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Background: Non-invasive Cardiovascular imaging (NICI), including cardiovascular
magnetic resonance (CMR) imaging provides important information to guide the
management of patients with cardiovascular conditions. Current rates of NICI use
and potential policy determinants in the United States of America (US) and England
remain unexplored.
Methods: We compared NICI activity in the US (Medicare fee-for-service, 2011–2015)
and England (National Health Service, 2012–2016). We reviewed recommendations
related to CMR from Clinical Practice Guidelines, Appropriate Use Criteria (AUC), and
Choosing Wisely. We then categorized recommendations according to whether CMR
was the only recommended NICI technique (substitutable indications). Reimbursement
policies in both settings were systematically collated and reviewed using publicly
available information.
Results: The 2015 rate of NICI activity in the US was 3.1 times higher than in England
(31,055 vs. 9,916 per 100,000 beneficiaries). The proportion of CMR of all NICI was
small in both jurisdictions, but nuclear cardiac imaging was more frequent in the US in
absolute and relative terms. American and European CPGs were similar, both in terms
of number of recommendations and proportions of indications where CMR was not the
only recommended NICI technique (substitutable indications). Reimbursement schemes
for NICI activity differed for physicians and hospitals between the two settings.
Conclusions: Fee-for-service physician compensation in the US for NICI may
contribute to higher NICI activity compared to England where physicians are salaried.
Reimbursement arrangements for the performance of the test may contribute to the
Petersen et al. Cardiac Imaging; US versus England
higher proportion of nuclear cardiac imaging out of the total NICI activity. Differences in
CPG recommendations appear not to explain the variation in NICI activity between the
US and England.
Keywords: imaging, nuclear cardiology and PET, diagnostic testing, computerized tomography, magnetic
resonance imaging, imaging
INTRODUCTION
Many patients with suspected or known cardiovascular diseases
benefit from non-invasive cardiovascular imaging (NICI) to help
reach correct diagnoses, to risk stratify and to guide clinical
management. Nuclear cardiac imaging and echocardiography
have been long established, but more recently cardiovascular
magnetic resonance (CMR) and cardiac computed tomography
(CT) have become available to broaden the options available to
cardiologists when considering the best investigations for their
patients. All NICI techniques have advantages and disadvantages,
and thus, play an important role in clinical practice. However,
CMR has the benefit of combining high diagnostic accuracy with
the lack of radiation, and robust diagnostic accuracy that is not
affected by suboptimal image quality due to poor echo windows.
Anecdotally, England is often referred to as an exemplar of
how CMR can be established as a serious contender amongst
other NICI modalities. In contrast, the United States (US) is
often considered to provide insufficient clinical CMR activity
compared to other tests, in particular to nuclear cardiac imaging
(1). Evidence to support these claims is currently lacking, recent
trends in NICI use are largely unknown, and there is likely
substantial geographical variation in NICI activities.
Clinical practice guidelines (CPGs) and reimbursement
schemes may be two of the key determinants of trends in NICI
use. CPGs have been developed for a variety of cardiovascular
diseases, containing specific indications for CMR in the US (2–
16) and Europe (16–28). These have been summarized by von
Knobelsdorff et al. (29, 30), but since, new guidelines or updates
to guidelines have been released (31–42). Between 2006 and 2011,
appropriate use criteria (AUC) were developed and published—
led by the American College of Cardiology Foundation (ACCF)
with input from many professional bodies (43–45). Moreover,
the Society for Cardiovascular Magnetic Resonance (SCMR)
published five clinical situations in which CMR should not be
performed as part of the Choosing Wisely program in 2014
(46). Reimbursement schemes were found to impact activity at
physician-level (47, 48) and center-level (49–51).
Interestingly, financial incentives through reimbursement
schemes were also found to counter CPGs recommendation,
in particular if healthcare technology is substitutable. This has
been highlighted in the case for cemented and uncemented hip
replacements performed in the National Health Service (NHS)
(52), possibly also applying to NICI technologies as, for example,
a CMR scan to determine the significance of coronary artery
disease could be substituted by another NICImodality, according
to the CPGs.
The aim of this study was to determine trends in NICI activity
for the US (fee-for-service Medicare) and England (NHS), and
to assess whether variation in trends in NICI activity may be
influenced by differences in CPGs and reimbursement schemes
across settings.
METHODS
Cardiovascular Magnetic Resonance and
Other Non-invasive Cardiovascular
Imaging Activity
Activity data for NICI in the US and England were available
for people with public health insurance (Medicare fee-for-service
in the US and NHS in England) for a 5-year period. Medicare
data was accessed through the American College of Cardiology
via a paid license, but excluded patients enrolled into Medicare
Advantage Plans (53). Americans older than 65 years or living
with a disability are eligible for health insurance through the
federal Medicare program.
Traditional Medicare (fee-for-service) provides coverage to
∼32 million Americans, while the remaining ∼20 million
beneficiaries are enrolled into Medicare Advantage plans
(see Supplementary Material 5 for exact 2011–2015 data).
Information on NICI activity was extracted and aggregated for
calendar years 2011 to 2015, using relevant Current Procedural
Terminology (CPT) codes (Supplementary Materials 1–4 for
detail). As we cannot perform sub- analyses of NICI activities
by indication, CPT codes were combined (4 for CCT, 6 for
echocardiography, 4 for CMR, 11 for nuclear cardiac imaging
investigations). Data are presented based on absolute numbers
of activity after transformation to per 100,000 beneficiary users
(Supplementary Material 5). Annual percentage change (%) in
activity was calculated as the ratio of yearly activity and activity
recorded in the previous year times 100.
For England, we requested extracts from the Diagnostic
Imaging Dataset (DID) held by NHS Digital (54). We selected
72 SNOMED-CT codes (9 for CCT, 16 for CMR, 34 for nuclear
cardiac imaging investigations, see Supplementary Material 6)
from a total of 2458 SNOMED- CT codes for procedures
captured in DID. Aggregate activity data was provided annually
for a 5-year period, from (financial) years 2012/13 to 2016/2017,
and separately for categories CMR, CCT, and nuclear cardiac
imaging. Because DID does not cover echocardiography
activities accurately, we used the Monthly Diagnostic Waiting
Times and Activity (DM01) dataset to extract activities for
echocardiography as advised by NHS Digital (55). The NHS
provides healthcare services to a total of 54.3 million people and
is free at the point of access. To ensure comparability with the
population covered by Medicare, we restricted our denominator
to 10.1 million people aged 65 years or older in England based
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BOX 1 | Substitutability in guideline-based recommendations as a potential determinant of NICI use—a two center pilot study in the US and England.
Objective: To determine whether substitutability of NICI techniques in guideline-based recommendations could be a driver of geographical variation in NICI use.
Methods: Consecutive CMR reports were anonymized. Blinded to the categories of whether modalities were substitutable for indications, a cardiologist (AK)
independently retrospectively categorized consecutive June 2018 CMR reports from one large academic center in the US (Hospitals of the University of Pennsylvania-
Penn Presbyterian) and one in England (Barts Health NHS Trust) according to the indication from any of the CPGs and AUCs. Another cardiologist (SEP) then
determined the frequency of CMR scans performed compliant with the recommendations and the frequency of CMR scans performed with substitutable indications.
A two-sided Chi-square test was performed to compare frequencies of CMR activity with substitutable guideline-based indications between an academic hospital in
the US and in England. A p-value of equal or <0.05 was considered statistically significant.
Results: At the Hospitals of the University of Pennsylvania-Penn Presbyterian, out of 129 consecutive CMR reports, 117 reports could be categorized, and all of
these were indicated (i.e., CPG class I, IIa or IIb or AUC category “appropriate” or “uncertain”). Of the 117 reports, 51 reports had substitutable indications. Thus,
43.6% of scans performed and with a categorizable indication could be substituted by a different imaging test without deviation from the guidelines. At Barts Health
NHS Trust, out of 100 consecutive CMR reports assessed, 93 reports could be categorized, and all of these were indicated (i.e., CPG class I, IIa or IIb or AUC category
“appropriate” or “uncertain”). Of the 93 reports, 33 reports had substitutable indications. Thus, 35.5% of scans performed and with a categorizable indication could
be substituted by a different imaging test without deviation from the guidelines. These findings were not statistically different between the US and England (Chi-square
= 1.419, p = 0.234).
Interpretation: Our findings suggest that clinical practice between the US and England in this CMR two-academic-center pilot may not differ with regards to the
frequency of CMR use for recommended indications that did not favor one NICI technique over another. Substitutability is unlikely a major driver of variation in NICI
activities.
on official statistics published by the Office for National Statistics
(56). To account for the proportion of activity linked to our
target population, we adjusted the absolute number of activity by
60 percentage points based on the average proportion of NICI
activity linked to patients aged 65 years or older. This approach
was guided by evidence from the literature and was selected
because of an absence of complete activity data disaggregated
by age for each NICI covered in this study (57, 58). We then
transformed the adjusted number of activity to per 100,000
beneficiary users, and derived annual percentage changes (%) in
activity. Sensitivity analyses investigating the impact of varying
adjustment points (i.e., at 50% and 70%) on activity in England
compared to the US was performed.
Clinical Practice Guidelines
Indications relevant to CMR were collated and extracted from
US-based (American Heart Association—AHA or American
College of Cardiology—ACC involvement) and European- based
CPGs. This was based on work published by von Knobelsdorff
et al. (29, 30) but updated using latest revisions of CPGs
published until 08/31/2018 (31–42). The extraction contained
the class of recommendation (I, IIa, IIb, and III) and the level
of evidence (A–C). In addition, we collated indications and
recommendations from the American College of Cardiology
Foundation (ACCF) appropriate use criteria (AUC) (43). AUC
for CMR—led by ACCF with input frommany other professional
bodies—were included in this list of indications with extraction
of the recommendation and score [A = appropriate (score 7–
9), U = uncertain (score 4–6), and I = inappropriate (score
1–3)]. This indication list was complemented with the five
recommendations stating when not to use CMR from the
Choosing Wisely programme (46). For the combined list, we
separated the indications into four categories: substitutable and
recommended [Y]; substitutable and not recommended [(Y)];
not substitutable and recommended [N]; and not substitutable
and not recommended [(N)]. A two-center pilot study was
conducted to assess the role of guideline-based recommendations
on NICI use (see Box 1).
Cardiac Imaging Reimbursement
To match NICI activity, we collated information on NICI
reimbursement covered by traditional Medicare and the NHS.
For Medicare and non-invasive imaging, the description has
been informed by discussions with members of the Society
for Cardiovascular Magnetic Resonance (SCMR) US Working
Group (VAF, TSEA), which aims to support CMR activity. Work
by Ferrari et al. provided an overview into the relevant aspects of
the US payment system with regards to cardiovascular imaging
(1). This was complemented by 2018 tariffs outlined on the
Centers for Medicare & Medicaid Services website. The final
2018 cardiac imaging payment systems can be downloaded as
addendum A (59). The relevant tariffs can be found according
to the codes that capture the imaging modalities (2018 Medicare
Physician Fee Schedule final rule) (53, 60). For the NHS, we
extracted information from NHS England (i.e., the executive
non-departmental body in charge of the healthcare budget and
oversight of commissioning services) and NHS Improvement
(i.e., the non-departmental body in charge of service provision
of local healthcare providers) 2018/19 National Tariff Payment
System (61), and annex A (i.e., national prices and national tariff
workbook) (62).
To assess whether physician payment is significantly different
between modality reporting, insights from three cardiac imaging
physicians in the US and in England were sought to estimate
the number of typical reports for each modality per hour.
This average reporting volume multiplied by the fee-for-
service provided estimates of hourly earnings and allowed
investigating whether financial incentives at the physician-level
could influence the choice of NICI modality.
Statistical Analysis
Two-sided Chi-square tests were performed to compare
frequencies of CMR activity with substitutable guideline-based
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indications between the US and Europe. A p-value of equal
or <0.05 was considered statistically significant. The analysis
was performed using a web-based social science statistics
platform (63).
RESULTS
CMR and NICI Activity
CMR activity per 100,000 beneficiaries with public health
insurance in the US (from 2011 to 2015) and for England
(from 2012 to 2016) are displayed in Figures 1, 2 and Table 1.
During the study period, in England, echocardiography remained
the most commonly performed NICI test (87–89%), followed
by nuclear cardiac imaging (6–10%), cardiac CT (2–4%), and
CMR (1%).
Similarly, in the US, echocardiography was the most
commonly performed NICI test (75–78%), followed by nuclear
cardiac imaging (21–25%), cardiac CT (<1%), and CMR (<1%)
(Table 1).
CMR activity is higher (0 to 1.4-fold) in England compared
to the US per 100,000 beneficiaries. This is also the case for
cardiac CT (1.1 to 1.4-fold). Nuclear cardiac imaging and
echocardiography are two techniquesmore frequently performed
in the US compared to England: by 10.3–10.4 times and 2.9–3.7
times, respectively (Table 1).
Trend analysis by modality and country suggested that in
England the total NICI activity has increased by a factor of 1.31,
with increases in all imaging modalities (by factors of 2.40 for
CMR, 2.22 for cardiac CT and 1.33 echocardiography)—except
nuclear cardiac imaging (reduction by 15%). Unlike in England,
in the US the total NICI activity has decreased by 8%. This is
driven by reductions in echocardiography (−4%) and nuclear
cardiac imaging (−21%), which in absolute numbers are the
largest contributors to NICI activity. Cardiac CT and CMR use
have increased in the US by factors of 1.31 and 1.29, respectively,
but relative growth rates are smaller compared to England.
Clinical Practice Guidelines
The most common CMR indications are similar in the US and in
Europe (i.e., including England; see Table 2). Cardiomyopathies,
myocarditis, heart failure and viability are among the top three
indications in the mainly US based SCMR Registry (formerly
known as GCMR) (64), the EuroCMR Registry (65), and
according to a 2011 BSCMR survey, among CMR centers in the
United Kingdom (66).
The result of the extraction of individual recommendations
from the European and the American CPGs and the AUC, and
the statements in the Choosing Wisely program are summarized
in Supplementary Material 7. The ACC/AHA have published
12 CPGs or updates between 2008 and 08/31/2018, which
contain 67 specific CMR recommendations. The European
FIGURE 1 | Non-invasive cardiac imaging activity in England and its change over 5 years. Source: Diagnostic Imaging Dataset, NHS Digital for Nuclear cardiac
imaging, cardiac CT and cardiac MR (Snomed-CT codes used, see Supplementary Material 6); Echocardiography data was taken from the Monthly Diagnostic
Waiting Times and Activity (DM01) dataset.
Frontiers in Cardiovascular Medicine | www.frontiersin.org 4 January 2021 | Volume 7 | Article 617771
Petersen et al. Cardiac Imaging; US versus England
FIGURE 2 | Non-invasive cardiac imaging activity in US and its change over 5 years. Source: Medicare data accessed via the American College of Cardiology. Details
of which CPT codes used can be found in the Supplementary Materials 1–5.

































































































Total 33,654 7,551 32,475 8,039 31,549 8,564 31,125 9,171 31,055 9,916
The total (sum) of the components may contain rounding errors; Data sources as described in Figures 1, 2. Activity for England restricted to beneficiaries aged 65 years and older.
Society of Cardiology (ESC) has published 15 CPGs with 68
CMR recommendations between 2010 and 08/31/2018. The
AUC related to CMR contain 30 recommendations published
in 2006. Amongst recommendations that were not class III,
or categorized as inappropriate in AUC, or part of the five
Choosing Wisely program recommendations, the following
proportions were substitutable by an alternative NICI test:
for ACC/AHA CPGs there were 40 out of 67 (60%), for
the ESC CPGs there were 38 out of 68 (56%), and for the
AUC there were 11 out of 30 (37%) recommendations. In
pairwise comparisons, only the ACC/AHA recommendations
had significantly more substitutable indications compared with
AUC (Chi-square = 4.4, p = 0.036). Importantly, there was
no statistically significant difference between the ACC/AHA
and the ESC recommendations (Chi-square 0.202, p = 0.653
for ACC/AHA vs. ESC; Chi-square 3.075, p = 0.079 for ESC
vs. AUC).
Reimbursement Schemes for Non-invasive
Cardiovascular Imaging
Medicare reimbursement schemes for NICI differ depending on
the setting it is performed in, for example the hospital-based
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inpatient, hospital-based outpatient, or physician office/imaging
center (Table 3). Inpatient investigations are reimbursed as part
of hospital patient episodes according to a diagnosis-related
group (DRG), thus the DRG related amount remains constant
whether or not NICI was performed. In contrast, most physicians
are paid separately through Medicare for the activity of
image reading and reporting. Outpatient investigations in the
hospital setting attract payment according to the outpatient
prospective payment system (OPPS) via an ambulatory payment
classification (APC). Similar to the inpatient setting, physicians
involved in reading and reporting may charge Medicare
separately for this professional activity (Tables 4, 5). In the
third setting of performing NICI in a physician’s office, or
dedicated imaging facility, payment occurs in two ways: a
technical component and a professional component according
to the Medicare Physician Fee Schedule. There is a range of
fees (i.e., represented in 2018 US Dollars) the centers attract
with the largest amount for nuclear cardiac imaging (up to
$1202 + physician fees). Reimbursement is lower for CMR (at
$682), cardiac CT (at $253), and echocardiography (at $487), plus
physician fees.
The NHS provides free healthcare at point of entry to
∼54.3 million people in England (67). Similar to the US,
reimbursement differs for NICI performed for inpatient and
outpatient settings. For inpatients, the reimbursement is through
payments based on the inpatient hospital episode classed
according to a Healthcare Research Group (i.e., HRG++),
while for outpatients, hospitals are paid the national tariff
for the relevant imaging modality. National tariff 2018 prices
were £448 (∼$578) for CMR, £216 (∼$279) for cardiac CT,
£159 to £190 (∼$204–$245) for nuclear cardiac imaging, and
£64–£179 (∼$83–$231) for echocardiography. A key difference
to the US is that hospital doctors are salaried and thus
not paid on a fee-for-service basis as is the case in most
centers in the US (Table 4). There are no NHS imaging
facilities run outside hospitals that would be reimbursed
differently. Given the above prices, the relative payment at
TABLE 3 | Overview of non-invasive cardiac imaging reimbursement schemes
from public healthcare provision.
Setting [center/physician fees] US England
Hospital inpatient [center] DRG HRG++
Hospital inpatient [physician] Charges Medicare NHS salaried
Hospital outpatient [center] APC National tariff
Hospital outpatient [physician] Charges Medicare NHS salaried
Office imaging facility [center] MPFS technical
component
N/A
Office imaging facility [physician] MPFS professional
component
N/A
Details are listed for the US and England according to the settings and at the level of the
center and the physician performing the scan and reporting.
DRG, diagnosis related group; HRG, healthcare resource group; MPFS, Medicare
Physician Fee Schedule; APC, ambulatory payment classification.
the center-level is higher for nuclear cardiac imaging and
echocardiography compared to CMR and cardiac CT in the
US when compared to England. This observation is more
pronounced in the US hospital outpatient setting than in the
office-based setting.
Although payment at the physician-level varies from
salaried physicians in England to a payment system based
on fee-for-service in the US, there appears to be no major
driver to perform one particular NICI test over another
within the US fee-for-service reimbursement schemes
(Table 5). Cardiac CT attracts the highest hourly rate
($542) followed by echocardiography ($504), CMR ($465),
and then nuclear cardiac scan reporting ($325). CMR
hourly reporting rates were 1.4 times higher than for
nuclear reporting.
DISCUSSION
In this study, we used Medicare fee-for-service and NHS Digital
data to investigate NICI activities. We find that in 2015, the US
performed over three-times more NICI compared to England
(31,055 vs. 9,171 per 100,000 beneficiaries). CMR activity in
the US was 0–1.5 times smaller compared to England, which
contrasts with the 10.3–10.4 times higher nuclear cardiac imaging
activity in the US. We find no evidence to suggest that
recommendations in international CPGs may be linked to the
observed differences in NICI activity. Between both countries,
financial remuneration varies at the physician-level (fee-for-
service vs. salaries), which may contribute to the comparatively
high NICI activity in the US. Payment mechanisms for the scan
component of the NICI may also be related to the relatively more
frequent activity of nuclear cardiac imaging compared to the use
of CMR in the US, as nuclear cardiac imaging is incentivized
through higher fees (up to $1202 vs. up to $682, respectively).
CPGs do not appear to influence relative NICI use. We
found American and European recommendations of CMR use
to be similar in terms of total number of recommendations
and proportion of recommendations in which CMR could
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TABLE 4 | Outpatient reimbursement for 2018.
Setting [center/physician
fees]
US (Hospital-based outpatient) US (Office imaging facility) England (NHS Hospital)










RD08Z (non-contrast): £325 incl. £22 report
RD10Z (pre- and post- contrast): £448 incl. £20 report
CMR—Physician Charges Medicare (similar to professional
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RD28Z (Complex CT scan):
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RN20Z (MPS): £159 incl.
£26 report
RN21Z (MPS, stress only):
£216 incl. £26 report RN22Z (MUGA): £190 incl.
£19 report
Nuclear—Physician Charges Medicare (similar to professional









RD51A-C (simple echo, age- dependent): £64–89
EY50Z (complex echo):
£176 (or £430 if done as day case)
EC21Z (complex echo for CHD): £179 (or £620 if done
as day case)
Echo—Physician Charges Medicare (similar to professional
component of MPFS, next column) CPT 93350: $72.72
CPT 93351: $87.12
NHS salaried
Details are listed for the US and England according to the settings and at the level of the center and the physician performing the scan and reporting.
CPT, Current Procedure Technology; APC, ambulatory payment classification; CHD, congenital heart disease; CCT, cardiac computed tomography; CMR, cardiovascular magnetic
resonance; MPFS, Medicare Physician Fee Schedule.
CMR CPT codes.
75557 Cardiac MR imaging for struct and morph w/o contrast.
75559 Cardiac MR imaging for struct and morph w/o contrast w/stress imaging.
75561 Cardiac MR imaging for struct and morph w/o contrast, followed by contrast, and further sequences.
75563 Cardiac MR imaging for struct and morph w/o contrast, followed by contrast, and further sequences, w/stress imaging.
Cardiac CT CPT codes.
75571 CT heart w/o contrast, w/quantitative eval of coronary calcium.
75572 CT heart w/contrast for eval of cardiac struct and morph.
75573 CT heart w/contrast for eval of cardiac struct and morph (congenital heart disease).
75574 CT angio heart, coronary arteries and bypass grafts w/contrast.
Cardiac nuclear CPT codes.
78452 MPI, tomographic (SPECT) (inc. attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when
performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection.
78453 Myocardial perfusion imaging, planar (inc. qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed);
single study, at rest or stress (exercise or pharmacologic).
78454 MPI, planar (inc. qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest
and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection.
Cardiac echo CPT codes.
93350 Echo rest and cv stress test w/interp and report.
93351 Echo rest and cv stress test w/interp and report including electrocardiographic monitoring w/physician supervision.
be substituted by other NICI techniques. Contrary to our
hypothesis that these substitutable indications were more
frequent referral reasons in England than in the US, findings
from our pilot study, focusing on data from one US- based
and one England-based CMR center, show that the proportions
were similar.
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NICI activity was 3.4-fold higher in the US compared with
England in 2015. This may partly be explained by the fee-for-
service payment for physicians in the US compared to salaried
doctors in England. In fact, evidence on the effect of salaries
on reducing activity compared with fee-for- service payments
have been found in pediatric and primary care settings (68–
70). However, the payment for different NICI reports appears
proportionate if calculated as an hourly rate, for example nuclear
cardiac imaging reporting attracts no higher pay over CMR or
cardiac CT reporting.
Although NICI activity data was available in the US
(Medicare fee-for-service, excluding patients enrolled in
Medicare Advantage Plan) and England (NHS), because
its provision is mandatory to providers of Medicare and
NHS services, this study relied on the accuracy of coding
information. Population demographics are likely to vary between
Medicare and NHS beneficiaries. By definition, most Medicare
beneficiaries will be 65 years and older, while the NHS covers
people of all ages. We addressed this concern by estimating
the adjusted number of activities for NHS beneficiaries aged
65 years and older, allowing for age-wise comparisons in NICI
activity between both health care systems. While an adjustment
factor of 60 percent was chosen on the basis of disaggregated
information on echocardiography activity from NHS Digital
and CMR activity by age in England from published literature,
this may not reflect the exact number of activity linked to the
target population. The adjustment factor was chosen because
of a lack of available activity data disaggregated by age group.
Sensitivity analyses addressing variation in the adjustment
factor (50 and 70%) suggested small changes to the NICI
activity per 100,000 beneficiaries, but importantly, differences
in activity between the US and England remained substantial
(see Supplementary Material 8). Moreover, overall findings
remained consistent when investigating NICI activity for the
whole NHS population, rather than as a subgroup, with increases
to the magnitude of difference in NICI activity between the US
and England (see Supplementary Material 9). Our objective in
this study was exploratory in nature; therefore, we cannot make
causal inferences about the relationship between NICI activity,
and potential policy predictors including financial incentives
and CPGs.
Future work should address other potential determinants of
NICI use and investigate whether activity numbers represent
over- or under-use of these diagnostic tests. There are several
determinants of NICI activity, all of which are context specific
(71). Unlike echocardiography and dedicated nuclear cardiac
equipment, cardiac CT and CMR activities are often competing
for scanner time with non-cardiac activity (e.g., brain scans).
Because this study focusses on NICI activity and reimbursement,
extrapolation without this consideration to sites where magnetic
resonance imaging and CT scanners are used for both cardiac
and non-cardiac activity. It is possible that NICI activity
is disincentivized by higher reimbursement for non-cardiac
activity, particularly if the service is provided by different
specialties (e.g., cardiology and radiology).
There are other important factors that influence CMR
activity levels, including the lack of experienced CMR
TABLE 5 | Estimated hourly physician Medicare reimbursement in 2018 for
reporting non-invasive cardiac imaging in the US according to Medicare Physician
Fee Schedule and estimated scans.
Modality ∼Professional





CMR 150 3.100 465
CCT
125 4.333 542
Nuclear 50 6.500 325
Echo 80 6.300 504
Source.
*3 US and 3 UK non-invasive imaging cardiologists’ estimate.
CMR, cardiovascular magnetic resonance; CCT, cardiac computed tomography; Nuclear,
cardiac nuclear investigations; Echo, echocardiography.
experts as well as knowledge and expectations of the
referring physician.
For example, it is possible that training of reporting physicians
may be lagging behind to supply sufficient certified NICI experts,
in particular to perform CMR that requires substantial clinical
exposure and knowledge. This presents an opportunity cost
for well-versed clinicians in other NICI modalities to train in
CMR. For newer indications, referring physicians may need to
be trained to be referring their patients for the most appropriate
NICI test. As nuclear cardiac scans are mostly performed by
cardiologists in the US, self-referral for nuclear cardiac scans
may be chosen to ensure the service is performed internally
(e.g., due confidence in own reports, reimbursement for this
service). As a consequence, the “ownership” (radiology/nuclear
medicine/cardiology) of the equipment and provision of certain
NICI services will determine relative NICI activity across many
healthcare systems.
Differences in reimbursement schemes through fee-for-
service physician payment in the US for NICI may contribute
to the three-times higher NICI activity compared to England
where doctors are salaried. Reimbursement arrangements for the
performance of the test without reporting fees may contribute to
the relatively higher proportion of nuclear cardiac imaging of the
total NICI activity, which may make CMR activity seem lower
in the US. We found that absolute CMR activity is higher in
England than in the US, suggesting that reimbursement factors
could be important drivers. Based on our analyses for a study
period from 2011 to 2016, CPGs do not seem to explain the
variation in NICI activity between both countries, although
we cannot discount that CMR use may have increased due to
an emphasis of its value in CPGs published after 2016. The
presented data provides a comprehensive insight into current
NICI activity, reimbursement arrangements and CPGs in the US
and Europe.
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